Embodiments generally relate to medication delivery. More particularly, embodiments relate to wearable drug delivery devices configured to monitor medication flow.
Drug delivery devices (e.g., infusion devices or pumps) can experience conditions that can lead to under-delivery or over-delivery of an infusate into a patient. For example, blockages in a fluid path (e.g., as caused by an occlusion) can cause a backup of fluid within the pump and a subsequent increase in fluid path pressure. When a blockage clears, the pressurized infusate can be delivered in a single bolus in an undesirable or unintended manner.
When air is trapped in the fluid path, changes in atmospheric pressure can cause the trapped air to expand or compress and to displace (e.g., by suction) fluid into or out of the patient. These situations can also cause under-delivery or under-delivery of the infusate into the patient. Swimming or flying are examples of common activities engaged in by a patient that can result in under-delivery and over-delivery without the patient's knowledge.
Additionally, when air is trapped in the fluid path, changes in ambient temperature can also cause the trapped air to expand or compress and to displace fluid into or out of the patient. Similarly, these situations can also cause under-delivery or over-delivery of the infusate into the patient. Swimming in the ocean or swimming in an unheated pool or using a heated blanket are examples of common activities engaged in by a patient that can result in under-delivery and over-delivery of the infusate without a patient's knowledge.
Many conventional drug delivery devices including infusion devices or pumps detect occlusions by monitoring the time it takes for the pump to actuate. This conventional approach can produce erroneous results based on variabilities within the drive system (e.g., due to friction, power sagging, mechanical variability of parts, etc.).
Even conventional systems that directly measure the pressure within the pump fluid path often do not detect changes in atmospheric pressure which can lead to over-delivery and under-delivery. These conventional systems typically utilize pressure sensors which measure pressure relative to atmospheric pressure and are incapable of detecting any change in atmospheric pressure which can lead to over-delivery and under-delivery without a patient's knowledge as described above.
Accordingly, what is needed is a drug delivery device with improved capabilities for detecting under-delivery and over-delivery conditions during intended delivery periods or unintended delivery periods that can be caused by a variety of factors including changes in atmospheric pressure.
This disclosure presents various systems, components, and methods related to a drug delivery device. Each of the systems, components, and methods disclosed herein provides one or more advantages over conventional systems, components, and methods.
Various embodiments include a wearable drug delivery device having a pump system. The pump system can be used to deliver a stored liquid drug or other therapeutic agent to a user or patient. An absolute pressure sensor can be positioned within the fluid path of the drug delivery device and/or pump system. The absolute pressor sensor can detect both ambient pressure (e.g., absolute or atmospheric pressure) and relative pressure (gage or pumping pressure). Based on the detected pressures, the effects of external ambient pressure on air with the pump system and/or fluid path can be determined during intended drug delivery events and unintended drug delivery events. In turn, under-delivery and/or over-delivery of the liquid drug can be determined. Based on the severity of the determined under-delivery or over-delivery of the liquid drug, alarms of different urgencies can be provided to the user. Other embodiments are disclosed and described including various embodiments directed to the use of a flow sensor to detect the aforementioned over-delivery and under-delivery conditions.
Various embodiments provide techniques for monitoring the absolute and relative pressures associated with a liquid drug pump system of a wearable drug delivery device. Based on the monitored pressures, an amount (e.g., corresponding to an over-delivery or an under-delivery) and direction (e.g., into or out of the pump system) of unintended liquid drug flow can be determined. If the amount of the unintended liquid drug exceeds one or more thresholds, one or more associated alarms can be provided to a user. Monitoring can be provided during intended drug delivery operations when the pump system is directed to provide the liquid drug to the user and during unintended drug delivery operations when the pump system is directed to not provide the liquid drug to the user. Other embodiments are disclosed and described.
The pressure sensor 202 can be an absolute pressure sensor that can detect both ambient pressure (e.g., absolute or atmospheric pressure) and relative pressure (e.g., gage or pumping pressure) introduced as the pump system 200 displaces fluid (e.g., the infusate stored in the reservoir 102) in the overall fluid path of the pump system (e.g., including the reservoir 102 and the fluid path component 106). By using an absolute pressure sensor as the pressure sensor 202, it is possible to measure the effects of external ambient pressure on air within the reservoir 102. Further, by using an absolute pressure sensor as the pressure sensor 202, it is possible to measure the effects of the internal pumping pressure changes due to pumping (e.g., expelling the infusate from the reservoir 102 for delivery to the patient). By measuring these effects, the pump system 200 can detect situations of possible over-delivery and/or under-delivery of the infusate to the patient due to both intended and unintended actions (e.g., during periods of intended delivery and periods of unintended delivery). Further, the pump system 200 can provide indications of such over-delivery and/or under-delivery conditions or situations to the patient, allowing the patient to respond accordingly.
The supporting mechanical structure 108 can provide structural support to the reservoir 102, the fluid path component 106, and/or the plunger drive mechanism 110. The supporting mechanical structure 108 is not limited to the presentation depicted in
The pump system shown in
During periods of operation—for example, when the pump system of
The pump system shown in
The pressure sensor 202 can be an absolute pressure sensor that can detect both ambient pressure (e.g., absolute or atmospheric pressure) and relative pressure (e.g., gage or pumping pressure) introduced as the pump system 200 displaces fluid (e.g., the infusate stored in the reservoir 102) in the overall fluid path of the pump system (e.g., including the reservoir 102 and the fluid path component 106). By using an absolute pressure sensor as the pressure sensor 202, it is possible to measure the effects of external ambient pressure on air within the reservoir 102. Further, by using an absolute pressure sensor as the pressure sensor 202, it is possible to measure the effects of the internal pumping pressure changes due to pumping (e.g., expelling the infusate from the reservoir 102 for delivery to the patient). By measuring these effects, the pump system 200 can detect situations of possible over-delivery and/or under-delivery of the infusate to the patient due to both intended and unintended actions (e.g., during periods of intended delivery and periods of unintended delivery). Further, the pump system 200 can provide indications of such over-delivery and/or under-delivery conditions or situations to the patient, allowing the patient to respond accordingly. This enables a drug delivery device that incorporates the pump system 200 to operate more effectively and safely and to provide an improved experience for the patient.
In various embodiments, the pressure sensor 202 can be integrated into the reservoir 102 as shown in
In various embodiments, the pressure sensor 202 can have a round body to simplify sealing against the reservoir 102 and/or the fluid path component 106. In various embodiments, an integral lip seal can be used to seal the interface between the body of the pressure sensor 202 and the reservoir 102 and/or fluid path component 106.
The pressure sensor 202 can be coupled to a monitoring component 204. The pressure sensor 202 can measure the absolute pressure of the reservoir 102 and/or the fluid path component 106 (e.g., the overall fluid path of the pump system 200) and can provide an output signal to the monitoring component 204. In various embodiments, the pressure sensor 202 can take continuous readings of the absolute pressure. The output signal from the pressure sensor 202 can indicate the measured or detected absolute pressure and/or any other measured, detected, or derived pressure value.
The monitoring component 204 can process the received signal from the pressure sensor 202. The monitoring component 204 can be implemented in hardware, software, or any combination thereof. In various embodiments, the monitoring component 204 can be implemented using a processor and associated memory and can execute one or more monitoring algorithms or processes as described herein. In various embodiments, the monitoring component 204 can be implemented as dedicated hardware (e.g., as an application specific integrated circuit (ASIC)). The monitoring component 204 can be a constituent part of the pump system 200, can be implemented in software as a computational model, or can be implemented external to the pump system 200 (e.g., remotely).
In various embodiment, the output signal generated by the pressure sensor 202 can be a voltage signal, a current signal, and/or an electrical charge signal. In various embodiment, the output signal generated by the pressure sensor can be a data signal (e.g., an analog or digital data signal) such as, for example, an inter-integrated circuit (I2C), serial peripheral interface (SPI), or any other known or customized synchronous or asynchronous data communication stream. In general, the output signal from the pressure sensor 202 can indicate a measured pressure. Further, the pressure sensor 202 and the monitoring component 204 can communicate over any known signaling protocol or standard including any known wired or wireless communication or signaling protocol. In various embodiments, the signal generated by the pressure sensor 202 for output and delivery to the monitoring component can be temperature compensated to remove or mitigate any error due to temperature changes. The monitoring component 204 can convert the signal received from the pressure sensor 202 into an indication of absolute pressure (e.g., pounds per square inch absolute (psia)).
The monitoring component 204 can generate a characterization of the fluid capacitance of the reservoir 102 and/or the fluid path component 106 (e.g., a model of the fluid capacitance of the overall fluid path of the pump system 200). Alternatively, the monitoring component 204 can be provided such information. For example, the monitoring component 204 can include a memory component or can access a memory component storing such information. In various embodiments, one or more components (e.g., external hardware components) can be used to generate characterizations of the fluid path fluid capacitance that can be provided to the monitoring component 204 in the form of data that can be stored, or integrally included as part of operational software. The characteristic fluid capacitance can be an input into a detection algorithm or monitoring process implemented by the monitoring component 204. The fluid capacitance can be considered to be the relationship between an internal pressure of the reservoir 102 and/or the fluid path component 106 (e.g., the overall fluid path of the pump system 200) and the volume of fluid necessary to achieve the specific pressure.
As will be appreciated by a person of ordinary skill in the art, the nature of fluid capacitance is roughly equivalent to electrical capacitance in which the infusate acts as electrical charge, internal gage pressure behaves as the positive voltage in an electrical circuit, the hydraulic stiffness of a fluid path acts as the electrical capacitance of a capacitor, and the fluid path outlet flow restriction acts as a resistor does in the electrical equivalent. Additionally, counter infusion pressure provided by the patient at the infusion site acts as the ground potential. Further, when counter-infusion pressure matches the infusion pressure, flow (e.g., to the patient) stops. If counter-infusion pressure exceeds internal gage pressure, counter flow (flow into the fluid path of the pump system 200 and away from the patient) can occur.
The fluid capacitance can be characterized using a numeric value, or a range of numeric values, or a variable model which defines the characteristic fluid capacitance of the overall fluid path of the pump system 200. In various embodiments, a memory associated with the monitoring component 204 can store values for characterizing the fluid capacitance associated with the pump system 200. In various embodiments, the one or more stored values can be based on characterization of the specific design of the pump system 200.
As the pump system 200 operates to expel the infusate from the reservoir 102 and into the fluid path component 106 for delivery to the patient, the fluid capacitance associated with the pump system 200 can change. For example, the fluid capacitance can change based on changes to the effective stiffness of the reservoir 102 as the plunger 104 is advanced further into the reservoir 102 by the plunger drive mechanism 110. As another example, changes in the stiffness of the supporting mechanical structure 108, the pump drive mechanism 110, or the interfaces between these components can cause the fluid capacitance to change. Accordingly, the monitoring component 204 can include a range of characterized fluid capacitance values that account for any such change. In various embodiments, the monitoring component 204 can be configured to use a function or other mathematical model capable of defining the change in fluid capacitance over the range of operation of the pump system 200—for example, from fully filled to empty. Based on an indication of the fluid capacitance—for example, by generating an estimate of the fluid capacitance over time as the pump system 200 operates—the monitoring component 204 can detect and determine, for example, any under-delivered fluid based on an indication of pressure provided by the pressure sensor 202.
By monitoring the absolute pressure within the fluid path of the pump system 200, the amount and direction of flow from the fluid path of the pump system 200 can be determined by the monitoring component 204. Based on determined changes in the pressure of the fluid path of the pump system 200, and the characteristic fluid capacitance of the fluid path of the pump system 200, a total net flow of fluid (e.g., the infusate) from a first point in time to a later, second point in time can be determined. Based on the amount and direction of flow error over time (e.g., unintended or undesired flow of the infusate into or out of the fluid path of the pump system 200), the monitoring component 204 can determine if an alert or other alarm should be issued to the patient.
During operation of the pump system 200, as the plunger 104 advances further into the reservoir 102, the fluid capacitance associated with the pump system 200 can change and the pressure associated with the pump system 200 can also change. The monitoring component 204, by monitoring the pressure and fluid capacitance of the pump system 200 over time, can determine net fluid flow over time—either intended or unintended and either into or out of the pump system 200 (or a drug delivery device in which the pump system 200 can be included). In various embodiments, to estimate an amount of fluid flow, the monitoring component 200 can estimate an amount of undelivered volume of fluid (e.g., the infusate within the fluid path or reservoir 102) at two different points in time.
Accordingly, based on data or information provided by the pressure sensor 202, the monitoring component 204 can monitor an amount of infusate delivered over time to determine if the amount is a proper or correct amount based on a predetermined level of intended infusate delivery. The monitoring component 204 can further determine if changes in physical conditions or the environment in which the pump system 200 operates can lead to under-delivery or over-delivery of the infusate during periods of delivery or non-delivery. The flow direction and the amount of fluid as determined by the monitoring component 204 can be compared to one or more operational thresholds, to determine if an alert should be issued to the patient. This allows the patient to more safely use the pump system 200 and to take corrective action if necessary.
In various embodiments, the pump system 200 and/or the monitoring component 204 can operate to monitor the following operational conditions (e.g., errors) associated with the pump system:
Further, in various embodiments, the pump system 200 and/or the monitoring component 204 (and/or a drug delivery device of which the pump system 200 can be a component) can operate to provide the following alarms as necessary based on monitoring flow direction and amount of flow:
For the first source of error listed above (i.e., deviation of total infusate delivered over time from intended delivery), the monitoring component 204 can monitor (e.g., continuously) the pressure in the fluid path of the pump system 200 from the start of an intended delivery event until the end of the intended delivery event during which, for example, a predetermined or desired amount of infusate is to be delivered. The monitoring component 204 can then compare the difference in the determined pressures (or the volume of undelivered fluid) to predetermined delivery thresholds. If the amount of infusate delivered is more than desired or intended, and exceeds a first threshold, then an alert or alarm can be provided to the user. If the amount of infusate delivered is less than desired or intended, and is less than a second threshold, then an alert or alarm can similarly be provided to the user. In this way, a patient can be made aware of under-delivery or over-delivery situations through pressure monitoring that enables flow amounts and directions to be determined.
In various embodiments, the alerts or alarms can be visual and/or audible and can include haptic and/or tactile feedback such as vibrational movement of the drug delivery device. Further, in various embodiments, the alarms can vary based on the type of alarm—for example, a first type of visual and/or audible alert for an over-delivery condition and a second, different visual and/or audible alert for an under-delivery condition. If the over or under-delivery condition stays within the set thresholds, then an alarm may not be provided (e.g., if the deviation from a desired delivery is minimal). Further, multiple thresholds can be established and compared such that more significant deviations from an intended delivery can trigger heightened alarm signals or indications or the patient.
In various embodiments, the thresholds can be dynamically adjusted. For example, the thresholds for comparison can be adjusted based on a de-rating factor that can be based on the total delivered amount of infusate and/or the current unmetabolized excess infusate remaining in the blood stream in the event of an over-delivery event. In various embodiments, the monitoring component 204 can determine an estimate of infusate yet to be delivered in the event of under-delivery by monitoring the capacity of fluid path pressure differential from the start of infusion.
In various embodiments, the monitoring component 204 can distinguish changes in pressure due to ambient (atmospheric) pressure changes from intended pumping pressure changes. In various embodiments, the monitoring component 204 can implement various filtering techniques including, for example, Bayesian nonlinear filters such as Kalman and/or particle filters to isolate and then compensate for random wandering pressure changes due to, for example, changing weather conditions. The monitoring component 204 can also employ band pass filtering to isolate pulsatile pumping pressure changes.
Atmospheric pressure can change with geographic location (e.g., altitude) as well as weather. Accordingly, the monitoring component 204 can include a rolling window filter for establishing or re-establishing a baseline atmospheric pressure. This baseline atmospheric pressure level can be used for comparison over any time period. In various embodiments, the baseline filter window implemented by the monitoring component 204 can be linked to the metabolization rate of the infusate when known which can be provided to the monitoring component 204.
As described above, the monitoring component 204 can include one or more thresholds and associated alarms that can be issued to a user. Further, as described above, multiple threshold levels and heightened alerts can be used for comparison to indicate an escalating intensity of alarm based on the degree of risk associated with any particular threshold being exceeded or not met—for example, based on the level of infusate delivery missed or the level of excessive infusate delivery.
In various embodiments, in the case of little to no delivery (e.g., due to an occlusion), thresholds can be set based on the specific risk of the infusate via a table of values stored in a memory (e.g., ROM and/or RAM memory or any other memory or look-up table) associated with the monitoring component 204
For the second source of error listed above (i.e., deviation of total infusate delivered over time from unintended delivery), the following can be contributing sources for any such deviation or error:
In various embodiments, the monitoring component 204 can monitor (e.g., sample) the pressure of the fluid path of the pump system 200 continuously (or semi-continuously to conserve power) during periods of intended non-delivery—that is, during times when the pump system 200 is not being directed to specifically provide the infusate to the patient. During these periods, the internal pressure of the fluid path of the pump system 200 is unlikely to change by more than an expected amount due to the narrow range of atmospheric pressure changes. By monitoring the fluid path pressure of the pump system 200, the monitoring component 204 can determine if any such changes in pressure are significant.
In situations where the atmospheric pressure can change by an amount more than an expected amount due to normal weather based atmospheric pressure (e.g., during flying on a commercial flight), the monitoring component 204 can determine the potential unintended delivery due to air expansion in the reservoir 104 and can alert the user to any potential risk associated with such determined unintended delivery. Additionally, the monitoring component 204 can alert the user of the opposite condition (e.g., back flow) that may occur following an increase in absolute pressure as would be experienced during normalization of aircraft cabin pressure upon landing during a flight.
Further, in situations where the atmospheric pressure can change by an amount more than an expected amount due to normal weather based atmospheric changes, but at a rate which is lower than typical air travel pressure changes (e.g., traversing altitude slowly as can happen when driving from a lower altitude to a higher altitude), the monitoring component 204 can determine the rate of change of atmospheric pressure. The monitoring component 204 can use this determined rate to properly adjust the intensity of alerts and/or alarms provided to the patient.
Overall, the monitoring component 204 can monitor pressure changes during periods of non-delivery (e.g., intended non-delivery) to determine if any fluid is unintentionally provided to the patient or being removed from the fluid path coupled to the patient. If the levels of unintended delivery exceed one or more thresholds during such periods, one or more associated alarms (e.g., of heightened intensity) can be provided to the user.
In various embodiments, the monitoring component 204 can use a rolling window low pass filter matched to the in vivo decay rate of the infusate within the patient's body, or based on a reasonable threshold which can be set by the user. Additional filtering techniques can be employed in other embodiments utilizing Kalman, particle, or non-linear filtering techniques.
In various embodiments, the pump system 200 can include a temperature sensor to alter the sampling frequency in response to the potential for expansion or contraction of air bubbles in the fluid path of the pump system 200. For example, if greater temperature swings are to be expected within the environment in which the pump system 200 operates, larger pressure swings may be expected to occur. Accordingly, monitoring and/or sampling of the pressure may be adjusted during such time periods to increase monitoring or sampling. The temperature sensor can be part of or can be coupled to the monitoring component 204 to provide a measure of temperature to the monitoring component 204.
The operational block diagram 300 illustrates components that can be implemented by or can be included within the monitoring component 204 when implemented in conjunction with the pressure sensor 202. The operational block diagram 300 illustrates the inputs and outputs of each component and the function or capabilities of each components. The operations and components shown can be implemented in hardware, software, or any combination thereof.
The operational block diagram 300 can include the following components: a calibration-compensation-conversion component 302, a delivery error estimation component 304, a delivery error tracking and alarm determination 306, an ambient pressure model component 308, an intended delivery model 3108, a time-based decay alert-alarm parameter storage component 312, and an alert-alarm actuator component 314. The operations and functionalities of these components are described below.
The calibration-compensation-conversion component 302 can be coupled to a pressure sensor (e.g., the pressure sensor 202) and can receive one or more signals from the pressure sensor as described above. The calibration-compensation-conversion component 302 can also receive one or more signals relating to calibration, conversion, or compensation parameters. The calibration-compensation-conversion component 302 can operate to determine and output fluid path pressure (e.g., psi) based on the signals from the pressure sensor. Accordingly, the calibration-compensation-conversion component 302 can output a fluid path pressure signal. The calibration, conversion, or compensation parameters can also operate to provide sensor calibration and/or compensation functions such as, for example, linearization of output, input/output offset correction, and/or temperature compensation.
The delivery error estimation component 304 can receive the fluid path pressure output signal from the calibration-compensation-conversion component 302. The delivery error estimation component 304 can also receive fluid capacitance values (e.g., system calibration values) and baseline pressure values as shown in
In various embodiments, to determine instantaneous volumetric delivery error, which can be represented as Verror(t), where “t” represent time, the delivery error estimate estimation component 304 can utilize a fluid capacitance value or values, which can be represented as Cfluid(ξ,t). Fluid capacitance is typically expressed in units of volume/pressure (e.g., in μL/psi for small pumping devices). “ξ” can represent an aggregated variability of the fluid capacitance which can vary both with time and with any number of system physical parameters (e.g., specific to each pumping device). The baseline ambient pressure, represented as P0(t), can be the baseline pressure at which the system is operating at any given time as provided by the ambient pressure model 308. The instantaneous fluid path pressure provided by the calibration-compensation-conversion component 302, represented as P(t), can be the instantaneous pressure measured at a given time. The instantaneous volumetric delivery error can therefore be expressed as: Verror(t)=[P(t)−P0(t)]*Cfluid(ξ,t).
The delivery error tracking and alarm determination component 306 can receive the instantaneous volumetric delivery error signal outputted by the delivery error estimation component 304. The delivery error tracking and alarm determination component 306 can also receive time-based de-rating factors, an ambient pressure model error, and an indication of intended volumetric delivery as shown in
The ambient pressure model 308 can receive the fluid path pressure signal from the calibration-compensation-conversion component 302. The ambient pressure model 308 can output an ambient pressure model error. The ambient pressure model 308 can track background ambient pressure changes to limit false alarms due to ambient pressure or back pressure changes. The ambient pressure model 308 can also track background ambient pressure changes to determine over-delivery and/or under-delivery due to significant pressure excursions.
The intended delivery model component 310 can receive pump control data (e.g., a count of the number of pulses delivered) and can receive pump characteristic performance data (e.g., a measure of volume per pulse delivery). The intended delivery model component 310 generate an indication of expected volumetric delivery as shown in
The time-based decay alert-alarm parameter storage 312 can receive and/or store system alert-alarm decay parameters. The time-based decay alert-alarm parameter storage 312 can output specific mathematical functions to de-rate the impact of instantaneous volumetric error over time. The time-based decay alert-alarm parameter storage 312 can ensure transient unintended delivery events do not accumulate in the system and lead to unnecessary alarms.
The alert-alarm actuator 314 can receive any alert-alarm signal from the delivery error tracking and alarm determination component 306. Based upon receipt of any alert-alarm signal, the alert-alarm actuator 314 can activate an alarm mechanism or component as described above including, for example, a visual, tactile, and/or audible alarm to notify the user of an urgent condition.
In contrast to the operation of the pump system 200 which can detect pressure and subsequently determine flow based on fluid capacitance of the fluid path of the pump system 200, the pump system 400 uses a flow sensor 402. The flow sensor 402 can be positioned directly in the flow path of the pump system 400 (e.g., in the fluid path component 106 as shown in
In general, the flow sensor 402 can be positioned anywhere along the fluid path of the pump system 400 including in a cannula coupled to the end of the fluid path component 106 leading to the patient. In various embodiments, the flow sensor 402 can be located just outside the reservoir 102 and before the hard cannula providing access to the patient. In various embodiments, the flow sensor 402 can be integrated into the hard cannula.
A variety of different types of flow sensors can be used for the flow sensor 402 such as, for example, a micro-electro-mechanical system (MEMS) thermal mass flow sensor, a paddle wheel, or other type flow sensor appropriately sized for the expected flow from the intended pumping action of the pump system 400 and/or the effect of ambient pressure changes on air trapped within the fluid path of the pump system 400.
The flow channel for the flow sensor 402 can be made from a variety of materials including, for example, glass, metal, or any other material that can provide adequate thermal conductance to detect changes in the thermal gradient in the flowing media (e.g., the infusate). The flow sensor 402 can be calibrated for the specific viscosity, thermal conductance, and flow channel convective coefficient, and external thermal changes (e.g., to provide temperature compensation).
The pump system 400 can provide similar functionality as the pump system 200 with the change of a flow sensor 402 being used instead of a pressure sensor as provided for in the pump system 200. To that end, the flow sensor 402 can be coupled to the monitoring component 204 with the monitoring component 204 configured to operate in conjunction with a flow sensor. The flow sensor 402 can take regular readings of flow through the fluid path of the pump system 400 and can output a signal to the monitoring component 204. The type of signal, format, and/or protocol of the signal of the output signal can be similar to the output signal provided by the pressure sensor 202 but with providing an indication of flow rather than pressure.
The monitoring component 204 can convert the signal from the flow sensor 402 to a measure of flow rate (e.g., in units of volume/time). In various embodiments, a flow rate in units of μL/minute can be used. In general, any representation of flow magnitude can be used.
To determine total flow over a given period of time, the monitoring component 204 can integrate the flow data to compute the total net volume dispensed over a given amount of time. This value of net total delivery can then be used to monitor over-delivery and/or under-delivery conditions during operation of the pump system 400 in a manner similar to that described above in relation to the pump system 200.
Accordingly, based on data or information provided by the flow sensor 402, the monitoring component 204 can monitor an amount of infusate delivered over time to determine if the amount is a proper or correct amount based on a predetermined level of intended infusate delivery. The monitoring component 204 can further determine if changes in physical conditions or the environment in which the pump system 400 operates can lead to under-delivery or over-delivery of the infusate during periods of intended delivery or intended non-delivery. The flow direction and the amount of fluid as determined by the monitoring component 204 can be compared to one or more operational thresholds, to determine if an alert should be issued to the patient. This allows the patient to more safely use the pump system 400 and to take corrective action if necessary.
Overall, the pump system 400 can monitor the same operation conditions and errors listed above in relation to the pump system 200 and can operate to provide the alarms indicated above as necessary based on monitoring flow direction and amount of flow during delivery periods and non-delivery periods (e.g., by monitoring net flow over set intervals of time of delivery or non-delivery). Accordingly, the discussion above of these features in relation to the pump system 200 are applicable to the pump system 400.
Further, the pump system 400 can adjust sampling of flow rates during (e.g., monitoring of flow rates) during periods of non-delivery—that is, during times when the pump system 400 is not being directed to specifically provide the infusate to the patient. Sampling of flow can be made continuously or semi-continuously to conserve power. In various embodiments, the pump system 400 can include an ambient pressure sensor to alter the flow sampling frequency in response to the potential for expansion or contraction of air bubbles in the fluid path. In various embodiments, the pump system 400—similar to the pump system 200—can include a temperature sensor to alter the flow sampling frequency in response to the potential for expansion or contraction of air bubbles in the fluid path, as described above in relation to the pump system 200.
The operational block diagram 500 can include the following components: a calibration-compensation-conversion component 502, a delivery error estimation component 504, a delivery error tracking and alarm determination 506, an ambient pressure model component 508, an intended delivery model 510, a time-based decay alert-alarm parameter storage component 512, and an alert-alarm actuator component 514, and an ambient pressure feedback component 516. The operations and functionalities of these components are described below.
The calibration-compensation-conversion component 502 can be coupled to a flow sensor (e.g., the flow sensor 402) and can receive one or more signals from the flow sensor as described above. The calibration-compensation-conversion component 502 can also receive one or more signals relating to calibration, conversion, or compensation parameters. The calibration-compensation-conversion component 502 can operate to determine and output fluid path flow (e.g., μL/min) based on the signals from the flow sensor. Accordingly, the calibration-compensation-conversion component 502 can output a fluid path flow signal indicating instantaneous flow rate. The calibration, conversion, or compensation parameters can also operate to provide sensor calibration and/or compensation functions such as, for example, linearization of output, input/output offset correction, and/or temperature compensation.
The delivery error estimation component 504 can receive the fluid path instantaneous flow rate output signal from the calibration-compensation-conversion component 502. The delivery error estimation component 504 can also receive fluid capacitance values (e.g., system calibration values), ambient pressure baseline values, and a clock signal (e.g., from an external clock) as shown in
The delivery error tracking and alarm determination component 506 can receive the instantaneous volumetric delivery error signal outputted by the delivery error estimation component 504. The delivery error tracking and alarm determination component 506 can also receive time-based de-rating factors, an ambient pressure model error, and an indication of intended volumetric delivery as shown in
The ambient pressure model 508 can receive an ambient pressure signal from the ambient pressure feedback component 516. The ambient pressure model 508 can output an ambient pressure model error. The ambient pressure model 508 can track background ambient pressure changes to limit false alarms due to ambient pressure or back pressure changes. The ambient pressure model 508 can also track background ambient pressure changes to determine over-delivery and/or under-delivery due to significant pressure excursions.
The intended delivery model component 510 can receive pump control data (e.g., a count of the number of pulses delivered) and can receive pump characteristic performance data (e.g., a measure of volume per pulse delivery). The intended delivery model component 510 can generate an indication of expected volumetric delivery as shown in
The time-based decay alert-alarm parameter storage 512 can receive and/or store system alert-alarm decay parameters. The time-based decay alert-alarm parameter storage 512 can output specific mathematical functions to de-rate the impact of instantaneous volumetric error over time. The time-based decay alert-alarm parameter storage 512 can ensure transient unintended delivery events do not accumulate in the system and lead to unnecessary alarms.
The alert-alarm actuator 514 can receive any alert-alarm signal from the Delivery error tracking and alarm determination component 506. Based upon receipt of any alert-alarm signal, the Alert-alarm actuator 514 can activate an alarm mechanism as described above including, for example, a visual and/or audible alarm to notify the user of an urgent condition.
The ambient pressure feedback component 516 can provide ambient pressure feedback (e.g., in psi) via an absolute pressure sensor (e.g., not sensing the fluid path). This ambient pressure feedback component 516 can be optional to help account for events in between flow sampling.
In various embodiments, the drug delivery device 100 can be provided to a user without any included drug or medicine. Under such a scenario, a user may, for example, fill a reservoir of the drug delivery device 600 with a medicine or drug (e.g., by transferring a fluid from a syringe to a reservoir of the drug delivery device 600).
The drug delivery device 600 can be an infusion device, including a drug delivery pump device as described herein. The drug delivery device 600 may provide a stored drug to a user over a relatively long period of time (e.g., over several days in small dosage amounts) or over a relatively short period of time (e.g., over a few hours to a day). In various embodiments, the drug delivery device 600 can be an OmniPod® (Insulet Corporation, Billerica, Mass.) insulin delivery device. The drug delivery device 600 can be a drug delivery device such as those described in U.S. Pat. Nos. 7,303,549, 7,137,964, or 6,740,059, each of which is incorporated herein by reference in its entirety.
In various embodiments, the drug delivery device can include the pump systems described herein including the pump system 200 or the pump system 400 as well as the corresponding implementations of the monitoring component 204 described in relation to
Various internal constituent components of the drug delivery device 600 are shown in
The pump reservoir 602 can hold or store the drug or medicine that can be delivered to a user (e.g., insulin). The pump reservoir 602 can be accessed or filled through the reservoir inlet 604. The reservoir inlet 604 can provide a path for transferring a fluid from outside of the drug delivery device 600 to inside the drug delivery device 600 for storage and subsequent delivery. The drug stored in the pump reservoir 602 can exit the pump reservoir 602 through the reservoir outlet 606 for delivery to the user. The drug delivery device 600 can include a pump for transferring the drug from the reservoir 602 to a user. In various embodiments, a plunger acting in conjunction with the reservoir 602 can operate as a pump to enable the stored fluid to be expelled for delivery to a patient through a fluid path (e.g., as described in relation to the pumps systems 200 and 400). When extracted by operation of the pump, the drug may follow a path from the reservoir 602 to an outlet of the drug delivery device 602 and then on to a patient.
The sensor 608 can be a pressure sensor (e.g., the pressure sensor 202) and can operate and provide the functionality described above. The sensor 608 can be incorporated into the fluid path of the drug delivery device 600 (e.g., incorporated into the reservoir 602). The sensor 608 can be coupled to a sensor assembly or sensor interface 610. The sensor assembly 610 can provide connectivity between the sensor 608 and the PCBA 612. The PCBA 612 can house or contain additional functional components for operating the drug delivery device 600 including, for example, a controller for operating the drug pump to deliver stored fluid from the reservoir 602 to the user. The PCBA 612 can further house or contain components related to user interaction or control components as well as user feedback components including, such as, any of the alarm mechanisms or components described herein. Signals can be transferred bidirectionally between the sensor 608 and the PCBA 612 (and any other components coupled to the PCBA 612) by way of the interface 610. The monitoring component 204 can be integrated across any number of components included in the drug delivery device 600 and can, in various embodiments, include a processor and associated memory, dedicated hardware, or any device capable of executing instructions (e.g., computer executable code, firmware, etc.).
The structural support component 614 can correspond to the structural support component 108 represented in
In various embodiments, during an operation to provide a drug to a user, when a pump pulse occurs, a sharp rise in pressure can be sensed, followed by a slow decay as the pulse exits a narrow pump cannula of a drug delivery device. By monitoring the pressure spike and the corresponding decay, any of the pump systems (e.g., pump systems 200 or 400) or drug delivery devices described herein can determine if fluid is flowing, or if there is in an occlusion.
Pressure spikes that may occur when a pulse is not being delivered can be due to external effects (e.g., flying, swimming, physiological changes). By comparing pressure changes to the characteristic fluid capacitance, techniques described herein can determine if unexpected under-delivery or over-delivery of the drug has occurred in real time. Further, by comparing delivery conditions to a baseline and non-delivery conditions to the baseline, under-delivery and over-delivery conditions may be detected, as described herein.
The pump systems (e.g., pump systems 200 or 400) or drug delivery devices described herein, including techniques described herein performed by these devices, can provide numerous benefits over conventional drug delivery devices. In particular, the techniques described herein can provide virtual real-time occlusion detection. Further, the techniques can distinguish an occlusion (e.g., a no flow or low flow condition) from an increase in back pressure (e.g., increased resistance with continual flow). Additionally, the techniques described herein can track and log data (e.g., pressure change information) related to excursions from stated altitude or depth specifications.
The following examples pertain to additional further embodiments:
Example 1 is a method comprising determining a first pressure at a start of a delivery operation for a liquid drug, determining a second pressure at an end of the delivery operation for the liquid drug, determining a fluid capacitance value of a fluid path used for the delivery operation of the liquid drug, and determining an intended liquid drug delivery amount, and determining a delivery error amount of the liquid drug based on the first and second pressures, the fluid capacitance value, and the intended liquid drug delivery amount.
Example 2 is an extension of Example 1 or any other example disclosed herein, further comprising determining the first and second pressures based on determining an absolute pressure.
Example 3 is an extension of Example 2 or any other example disclosed herein, further comprising comparing the delivery error amount to one or more thresholds.
Example 4 is an extension of Example 3 or any other example disclosed herein, further comprising determining an over-delivery condition when the delivery error amount is greater than a first threshold.
Example 5 is an extension of Example 4 or any other example disclosed herein, further comprising determining an under-delivery condition when the delivery error amount is less than a second threshold.
Example 6 is an extension of Example 5 or any other example disclosed herein, further comprising providing a first alarm in response to the over-delivery condition and providing a second, different alarm in response to the under-delivery condition.
Example 7 is an extension of Example 6 or any other example disclosed herein, wherein the first and second alarms comprise at least one of an audible, a visual, and a tactile indication.
Example 8 is an extension of Example 7 or any other example disclosed herein, further comprising adjusting an indication of urgency of at least one of the first and second alarms based on a determined severity of the over-delivery condition and the under-delivery condition, respectively.
Example 9 is an extension of Example 6 or any other example disclosed herein, further comprising dynamically adjusting the first and second thresholds.
Example 10 is an extension of Example 9 or any other example disclosed herein, further comprising dynamically adjusting the first and second thresholds based on a de-rating factor based on a determined total amount of delivered liquid drug.
Example 11 is an extension of Example 9 or any other example disclosed herein, further comprising dynamically adjusting the first and second thresholds based on a de-rating factor based on a determined unmetabolized excess amount of over-delivered liquid drug.
Example 12 is an extension of Example 9 or any other example disclosed herein, further comprising determining a rate of change of atmospheric pressure.
Example 13 is an extension of Example 12 or any other example disclosed herein, further comprising dynamically adjusting the first and second thresholds based on the determined rate of change of the atmospheric pressure.
Example 14 is an extension of Example 9 or any other example disclosed herein, further comprising determining a temperature.
Example 15 is an extension of Example 14 or any other example disclosed herein, further comprising dynamically adjusting the first and second thresholds based on the determined temperature.
Example 16 is an extension of Example 1 or any other example disclosed herein, further comprising determining an unintended delivery error amount of the liquid drug during a time outside of the delivery operation of the liquid drug.
Example 17 is an extension of Example 16 or any other example disclosed herein, further comprising comparing the unintended delivery error amount to one or more unintended delivery thresholds.
Example 18 is an extension of Example 17 or any other example disclosed herein, further comprising providing an alarm responsive to comparing the unintended delivery error amount to the one or more unintended delivery thresholds.
Example 19 is an apparatus comprising a reservoir configured to hold a liquid drug, a fluid path component configured to couple the reservoir to a user, a plunger configured to expel the liquid drug from the reservoir for delivery to the user, an absolute pressure sensor configured to detect atmospheric pressure and relative pressure, and a monitoring component configured to determine a delivery error amount during an intended delivery operation and an unintended delivery operation based on the atmospheric pressure and the relative pressure.
Example 20 is an extension of Example 19 or any other example disclosed herein, wherein the plunger is directed to expel the liquid drug from the reservoir during an intended delivery operation and is directed to not expel the liquid drug from the reservoir during an unintended delivery operation.
Example 21 is an extension of Example 20 or any other example disclosed herein, wherein the monitoring component indicates an over-delivery condition when the delivery error amount is greater than a first threshold and wherein the monitoring component indicates an under-delivery condition when the delivery error amount is less than a second, different threshold.
Example 22 is an extension of Example 21 or any other example disclosed herein, wherein the monitoring component is configured to generate an alarm signal based on a determined severity of at least one of the over-delivery condition and the under-delivery condition.
Example 23 is an extension of Example 22 or any other example disclosed herein, wherein the alarm signal comprises at least one of a visual, an audible, and a tactile alert.
Example 24 is an extension of Example 21 or any other example disclosed herein, wherein the monitoring component is configured to dynamically adjust the first and second thresholds.
Example 25 is an extension of Example 24 or any other example disclosed herein, further comprising a temperature sensor, the monitoring component configured to dynamically adjust the first and second thresholds based on at least one of a determined temperature and a de-rating factor based on a determined total amount of delivered liquid drug.
Certain embodiments of the present invention were described above. It is, however, expressly noted that the present invention is not limited to those embodiments, but rather the intention is that additions and modifications to what was expressly described herein are also included within the scope of the invention. Moreover, it is to be understood that the features of the various embodiments described herein were not mutually exclusive and can exist in various combinations and permutations, even if such combinations or permutations were not made express herein, without departing from the spirit and scope of the invention. In fact, variations, modifications, and other implementations of what was described herein will occur to those of ordinary skill in the art without departing from the spirit and the scope of the invention. As such, the invention is not to be defined only by the preceding illustrative description.
This application is a continuation of U.S. application Ser. No. 15/714,496, filed Sep. 25, 2017, which claims the benefit of U.S. Provisional Application No. 62/398,792, filed Sep. 23, 2016, which are incorporated herein by reference in their entirety.
Number | Name | Date | Kind |
---|---|---|---|
2797149 | Skeggs | Jun 1957 | A |
3631847 | Hobbs | Jan 1972 | A |
3634039 | Brandy | Jan 1972 | A |
3812843 | Wootten et al. | May 1974 | A |
3841328 | Jensen | Oct 1974 | A |
3963380 | Thomas, Jr. | Jun 1976 | A |
4055175 | Clemens et al. | Oct 1977 | A |
4146029 | Ellinwood, Jr. | Mar 1979 | A |
4151845 | Clemens | May 1979 | A |
4245634 | Albisser et al. | Jan 1981 | A |
4368980 | Aldred et al. | Jan 1983 | A |
4403984 | Ash | Sep 1983 | A |
4464170 | Clemens et al. | Aug 1984 | A |
4526568 | Clemens et al. | Jul 1985 | A |
4526569 | Bernardi | Jul 1985 | A |
4529401 | Leslie | Jul 1985 | A |
4559033 | Stephen et al. | Dec 1985 | A |
4573968 | Parker | Mar 1986 | A |
4633878 | Bombardieri | Jan 1987 | A |
4657529 | Prince et al. | Apr 1987 | A |
4670007 | Wheeldon | Jun 1987 | A |
4743243 | Vaillancourt | May 1988 | A |
4755173 | Konopka et al. | Jul 1988 | A |
4781688 | Thoma et al. | Nov 1988 | A |
4781693 | Martinez et al. | Nov 1988 | A |
4854170 | Brimhall et al. | Aug 1989 | A |
4886499 | Cirelli et al. | Dec 1989 | A |
4900292 | Berry et al. | Feb 1990 | A |
4919596 | Slate | Apr 1990 | A |
4925444 | Orkin et al. | May 1990 | A |
4940527 | Kazlauskas et al. | Jul 1990 | A |
4975581 | Robinson et al. | Dec 1990 | A |
4976720 | Machold et al. | Dec 1990 | A |
4981140 | Wyatt | Jan 1991 | A |
4994047 | Walker et al. | Feb 1991 | A |
5007286 | Malcolm | Apr 1991 | A |
5097834 | Skrabal | Mar 1992 | A |
5102406 | Arnold | Apr 1992 | A |
5109850 | Blanco et al. | May 1992 | A |
5125415 | Bell | Jun 1992 | A |
5134079 | Cusack | Jul 1992 | A |
5153827 | Coutre | Oct 1992 | A |
5165406 | Wong | Nov 1992 | A |
5176662 | Bartholomew et al. | Jan 1993 | A |
5178609 | Ishikawa | Jan 1993 | A |
5207642 | Orkin et al. | May 1993 | A |
5237993 | Skrabal | Aug 1993 | A |
5257980 | Van Antwerp et al. | Nov 1993 | A |
5273517 | Barone et al. | Dec 1993 | A |
5299571 | Mastrototaro | Apr 1994 | A |
5308982 | Ivaldi et al. | May 1994 | A |
5342298 | Michaels | Aug 1994 | A |
5377674 | Kuestner | Jan 1995 | A |
5380665 | Cusack | Jan 1995 | A |
5385539 | Maynard | Jan 1995 | A |
5389078 | Zalesky | Feb 1995 | A |
5421812 | Langley | Jun 1995 | A |
5505709 | Funderburk et al. | Apr 1996 | A |
5505828 | Wong et al. | Apr 1996 | A |
5535752 | Halperin | Jul 1996 | A |
5558640 | Pfeiler et al. | Sep 1996 | A |
5569186 | Lord et al. | Oct 1996 | A |
5584813 | Livingston et al. | Dec 1996 | A |
5609572 | Lang | Mar 1997 | A |
5665065 | Colman et al. | Sep 1997 | A |
5685859 | Kornerup | Nov 1997 | A |
5693018 | Kriesel et al. | Dec 1997 | A |
5697899 | Hillman et al. | Dec 1997 | A |
5700695 | Yassinzadeh et al. | Dec 1997 | A |
5703364 | Rosenthal | Dec 1997 | A |
5714123 | Sohrab | Feb 1998 | A |
5716343 | Kriesel et al. | Feb 1998 | A |
5722397 | Eppstein | Mar 1998 | A |
5741228 | Lambrecht et al. | Apr 1998 | A |
5746217 | Erickson et al. | May 1998 | A |
5755682 | Knudson et al. | May 1998 | A |
5758643 | Wong et al. | Jun 1998 | A |
5800405 | McPhee | Sep 1998 | A |
5800420 | Gross et al. | Sep 1998 | A |
5801057 | Smart et al. | Sep 1998 | A |
5804048 | Wong et al. | Sep 1998 | A |
5817007 | Fodgaard et al. | Oct 1998 | A |
5820622 | Gross et al. | Oct 1998 | A |
5823951 | Messerschmidt | Oct 1998 | A |
5840020 | Heinonen et al. | Nov 1998 | A |
5848991 | Gross et al. | Dec 1998 | A |
5851197 | Marano et al. | Dec 1998 | A |
5858005 | Kriesel | Jan 1999 | A |
5865806 | Howell | Feb 1999 | A |
5871470 | McWha | Feb 1999 | A |
5879310 | Sopp et al. | Mar 1999 | A |
5902253 | Pfeiffer et al. | May 1999 | A |
5931814 | Alex et al. | Aug 1999 | A |
5932175 | Knute et al. | Aug 1999 | A |
5947911 | Wong et al. | Sep 1999 | A |
5971941 | Simons et al. | Oct 1999 | A |
5993423 | Choi | Nov 1999 | A |
5997501 | Gross et al. | Dec 1999 | A |
6017318 | Gauthier et al. | Jan 2000 | A |
6032059 | Henning et al. | Feb 2000 | A |
6036924 | Simons et al. | Mar 2000 | A |
6040578 | Malin et al. | Mar 2000 | A |
6049727 | Crothall | Apr 2000 | A |
6050978 | Or et al. | Apr 2000 | A |
6058934 | Sullivan | May 2000 | A |
6066103 | Duchon et al. | May 2000 | A |
6071292 | Makower et al. | Jun 2000 | A |
6072180 | Kramer et al. | Jun 2000 | A |
6077055 | Vilks | Jun 2000 | A |
6090092 | Fowles et al. | Jul 2000 | A |
6101406 | Hacker et al. | Aug 2000 | A |
6102872 | Doneen et al. | Aug 2000 | A |
6115673 | Malin et al. | Sep 2000 | A |
6123827 | Wong et al. | Sep 2000 | A |
6124134 | Stark | Sep 2000 | A |
6126637 | Kriesel et al. | Oct 2000 | A |
6128519 | Say | Oct 2000 | A |
6142939 | Eppstein et al. | Nov 2000 | A |
6143164 | Heller et al. | Nov 2000 | A |
6157041 | Thomas et al. | Dec 2000 | A |
6161028 | Braig et al. | Dec 2000 | A |
6162639 | Douglas | Dec 2000 | A |
6196046 | Braig et al. | Mar 2001 | B1 |
6200287 | Keller | Mar 2001 | B1 |
6200338 | Solomon et al. | Mar 2001 | B1 |
6214629 | Freitag et al. | Apr 2001 | B1 |
6226082 | Roe | May 2001 | B1 |
6244776 | Wiley | Jun 2001 | B1 |
6261065 | Nayak et al. | Jul 2001 | B1 |
6262798 | Shepherd et al. | Jul 2001 | B1 |
6270455 | Brown | Aug 2001 | B1 |
6271045 | Douglas et al. | Aug 2001 | B1 |
6280381 | Malin et al. | Aug 2001 | B1 |
6285448 | Kuenstner | Sep 2001 | B1 |
6309370 | Haim et al. | Oct 2001 | B1 |
6312888 | Wong et al. | Nov 2001 | B1 |
6334851 | Hayes et al. | Jan 2002 | B1 |
6375627 | Mauze et al. | Apr 2002 | B1 |
6379301 | Worthington et al. | Apr 2002 | B1 |
6402689 | Scarantino et al. | Jun 2002 | B1 |
6470279 | Samsoondar | Oct 2002 | B1 |
6475196 | Vachon | Nov 2002 | B1 |
6477901 | Tadigadapa | Nov 2002 | B1 |
6484044 | Lilienfeld-Toal | Nov 2002 | B1 |
6491656 | Morris | Dec 2002 | B1 |
6512937 | Blank et al. | Jan 2003 | B2 |
6525509 | Petersson et al. | Feb 2003 | B1 |
6528809 | Thomas et al. | Mar 2003 | B1 |
6540672 | Simonsen et al. | Apr 2003 | B1 |
6546268 | Ishikawa et al. | Apr 2003 | B1 |
6546269 | Kumik | Apr 2003 | B1 |
6553841 | Blouch | Apr 2003 | B1 |
6556850 | Braig et al. | Apr 2003 | B1 |
6558351 | Steil et al. | May 2003 | B1 |
6560471 | Heller et al. | May 2003 | B1 |
6561978 | Conn et al. | May 2003 | B1 |
6562001 | Lebel et al. | May 2003 | B2 |
6562014 | Lin et al. | May 2003 | B2 |
6569125 | Jepson et al. | May 2003 | B2 |
6572542 | Houben et al. | Jun 2003 | B1 |
6572545 | Knobbe et al. | Jun 2003 | B2 |
6574490 | Abbink et al. | Jun 2003 | B2 |
6575905 | Knobbe et al. | Jun 2003 | B2 |
6580934 | Braig et al. | Jun 2003 | B1 |
6618603 | Varalli et al. | Sep 2003 | B2 |
6633772 | Ford et al. | Oct 2003 | B2 |
6645142 | Braig et al. | Nov 2003 | B2 |
6653091 | Dunn et al. | Nov 2003 | B1 |
6662030 | Khalil et al. | Dec 2003 | B2 |
6669663 | Thompson | Dec 2003 | B1 |
6678542 | Braig et al. | Jan 2004 | B2 |
6699221 | Vaillancourt | Mar 2004 | B2 |
6718189 | Rohrscheib et al. | Apr 2004 | B2 |
6721582 | Trepagnier et al. | Apr 2004 | B2 |
6728560 | Kollias et al. | Apr 2004 | B2 |
6740059 | Flaherty | May 2004 | B2 |
6740072 | Starkweather et al. | May 2004 | B2 |
6751490 | Esenaliev et al. | Jun 2004 | B2 |
6758835 | Close et al. | Jul 2004 | B2 |
6780156 | Haueter et al. | Aug 2004 | B2 |
6810290 | Lebel et al. | Oct 2004 | B2 |
6837858 | Cunningham et al. | Jan 2005 | B2 |
6837988 | Leong et al. | Jan 2005 | B2 |
6846288 | Nagar et al. | Jan 2005 | B2 |
6862534 | Sterling et al. | Mar 2005 | B2 |
6865408 | Abbink et al. | Mar 2005 | B1 |
6890291 | Robinson et al. | May 2005 | B2 |
6936029 | Mann et al. | Aug 2005 | B2 |
6949081 | Chance | Sep 2005 | B1 |
6958809 | Sterling et al. | Oct 2005 | B2 |
6989891 | Braig et al. | Jan 2006 | B2 |
6990366 | Say et al. | Jan 2006 | B2 |
7008404 | Nakajima | Mar 2006 | B2 |
7009180 | Sterling et al. | Mar 2006 | B2 |
7016713 | Gardner et al. | Mar 2006 | B2 |
7018360 | Flaherty et al. | Mar 2006 | B2 |
7025743 | Mann et al. | Apr 2006 | B2 |
7025744 | Utterberg et al. | Apr 2006 | B2 |
7027848 | Robinson et al. | Apr 2006 | B2 |
7043288 | Davis, III et al. | May 2006 | B2 |
7060059 | Keith et al. | Jun 2006 | B2 |
7061593 | Braig et al. | Jun 2006 | B2 |
7096124 | Sterling et al. | Aug 2006 | B2 |
7115205 | Robinson et al. | Oct 2006 | B2 |
7128727 | Flaherty et al. | Oct 2006 | B2 |
7139593 | Kavak et al. | Nov 2006 | B2 |
7139598 | Hull et al. | Nov 2006 | B2 |
7144384 | Gorman et al. | Dec 2006 | B2 |
7171252 | Scarantino et al. | Jan 2007 | B1 |
7190988 | Say et al. | Mar 2007 | B2 |
7204823 | Estes et al. | Apr 2007 | B2 |
7248912 | Gough et al. | Jul 2007 | B2 |
7267665 | Steil et al. | Sep 2007 | B2 |
7271912 | Sterling et al. | Sep 2007 | B2 |
7278983 | Ireland et al. | Oct 2007 | B2 |
7291107 | Hellwig et al. | Nov 2007 | B2 |
7291497 | Holmes et al. | Nov 2007 | B2 |
7303549 | Flaherty et al. | Dec 2007 | B2 |
7303622 | Loch et al. | Dec 2007 | B2 |
7303922 | Jeng et al. | Dec 2007 | B2 |
7354420 | Steil et al. | Apr 2008 | B2 |
7388202 | Sterling et al. | Jun 2008 | B2 |
7402153 | Steil et al. | Jul 2008 | B2 |
7404796 | Ginsberg | Jul 2008 | B2 |
7429255 | Thompson | Sep 2008 | B2 |
7460130 | Salganicoff | Dec 2008 | B2 |
7481787 | Gable et al. | Jan 2009 | B2 |
7491187 | Van Den Berghe et al. | Feb 2009 | B2 |
7500949 | Gottlieb et al. | Mar 2009 | B2 |
7509156 | Flanders | Mar 2009 | B2 |
7547281 | Hayes et al. | Jun 2009 | B2 |
7569030 | Lebel et al. | Aug 2009 | B2 |
7608042 | Goldberger et al. | Oct 2009 | B2 |
7680529 | Kroll | Mar 2010 | B2 |
7734323 | Blomquist et al. | Jun 2010 | B2 |
7766829 | Sloan et al. | Aug 2010 | B2 |
7785258 | Braig et al. | Aug 2010 | B2 |
7806854 | Damiano et al. | Oct 2010 | B2 |
7806886 | Kanderian, Jr. et al. | Oct 2010 | B2 |
7918825 | O'Connor et al. | Apr 2011 | B2 |
7946985 | Mastrototaro et al. | May 2011 | B2 |
7972296 | Braig et al. | Jul 2011 | B2 |
8221345 | Blomquist | Jul 2012 | B2 |
8251907 | Sterling et al. | Aug 2012 | B2 |
8449524 | Braig et al. | May 2013 | B2 |
8547239 | Peatfield | Oct 2013 | B2 |
8810394 | Kalpin | Aug 2014 | B2 |
9061097 | Holt et al. | Jun 2015 | B2 |
9233204 | Booth et al. | Jan 2016 | B2 |
9486571 | Rosinko | Nov 2016 | B2 |
9743224 | San Vicente et al. | Aug 2017 | B2 |
9980140 | Spencer et al. | May 2018 | B1 |
10248839 | Levy | Apr 2019 | B2 |
10335464 | Michelich et al. | Jul 2019 | B1 |
10583250 | Mazlish et al. | Mar 2020 | B2 |
10737024 | Schmid | Aug 2020 | B2 |
10987468 | Mazlish et al. | Apr 2021 | B2 |
11197964 | Sjolund et al. | Dec 2021 | B2 |
11260169 | Estes | Mar 2022 | B2 |
20010021803 | Blank et al. | Sep 2001 | A1 |
20010034023 | Stanton, Jr. | Oct 2001 | A1 |
20010034502 | Moberg | Oct 2001 | A1 |
20010051377 | Hammer et al. | Dec 2001 | A1 |
20010053895 | Vaillancourt | Dec 2001 | A1 |
20020010401 | Bushmakin et al. | Jan 2002 | A1 |
20020010423 | Gross et al. | Jan 2002 | A1 |
20020016568 | Lebel | Feb 2002 | A1 |
20020040208 | Flaherty | Apr 2002 | A1 |
20020123740 | Flaherty | Sep 2002 | A1 |
20020128543 | Leonhardt | Sep 2002 | A1 |
20020147423 | Burbank et al. | Oct 2002 | A1 |
20020155425 | Han et al. | Oct 2002 | A1 |
20030023148 | Lorenz et al. | Jan 2003 | A1 |
20030050621 | Lebel et al. | Mar 2003 | A1 |
20030086074 | Braig et al. | May 2003 | A1 |
20030086075 | Braig et al. | May 2003 | A1 |
20030090649 | Sterling et al. | May 2003 | A1 |
20030100040 | Bonnecaze et al. | May 2003 | A1 |
20030130616 | Steil et al. | Jul 2003 | A1 |
20030135388 | Martucci et al. | Jul 2003 | A1 |
20030144582 | Cohen et al. | Jul 2003 | A1 |
20030163097 | Fleury et al. | Aug 2003 | A1 |
20030195404 | Knobbe et al. | Oct 2003 | A1 |
20030208113 | Mault et al. | Nov 2003 | A1 |
20030208154 | Close | Nov 2003 | A1 |
20030212379 | Bylund et al. | Nov 2003 | A1 |
20030216627 | Lorenz et al. | Nov 2003 | A1 |
20030220605 | Bowman, Jr. | Nov 2003 | A1 |
20040010207 | Flaherty et al. | Jan 2004 | A1 |
20040034295 | Salganicoff | Feb 2004 | A1 |
20040045879 | Shults et al. | Mar 2004 | A1 |
20040051368 | Caputo et al. | Mar 2004 | A1 |
20040064259 | Haaland et al. | Apr 2004 | A1 |
20040097796 | Berman et al. | May 2004 | A1 |
20040116847 | Wall | Jun 2004 | A1 |
20040122353 | Shahmirian et al. | Jun 2004 | A1 |
20040133166 | Moberg | Jul 2004 | A1 |
20040147034 | Gore et al. | Jul 2004 | A1 |
20040171983 | Sparks | Sep 2004 | A1 |
20040203357 | Nassimi | Oct 2004 | A1 |
20040204868 | Maynard et al. | Oct 2004 | A1 |
20040215492 | Choi | Oct 2004 | A1 |
20040220517 | Starkweather et al. | Nov 2004 | A1 |
20040241736 | Hendee et al. | Dec 2004 | A1 |
20040249308 | Forssell | Dec 2004 | A1 |
20050003470 | Nelson et al. | Jan 2005 | A1 |
20050020980 | Inoue et al. | Jan 2005 | A1 |
20050022274 | Campbell et al. | Jan 2005 | A1 |
20050033148 | Haueter et al. | Feb 2005 | A1 |
20050049179 | Davidson et al. | Mar 2005 | A1 |
20050065464 | Talbot et al. | Mar 2005 | A1 |
20050065465 | Lebel et al. | Mar 2005 | A1 |
20050075624 | Miesel | Apr 2005 | A1 |
20050105095 | Pesach et al. | May 2005 | A1 |
20050137573 | McLaughlin | Jun 2005 | A1 |
20050171503 | Van Den Berghe et al. | Aug 2005 | A1 |
20050182306 | Sloan | Aug 2005 | A1 |
20050192494 | Ginsberg | Sep 2005 | A1 |
20050192557 | Brauker et al. | Sep 2005 | A1 |
20050197621 | Poulsen et al. | Sep 2005 | A1 |
20050203360 | Brauker et al. | Sep 2005 | A1 |
20050203461 | Flaherty | Sep 2005 | A1 |
20050238507 | Dilanni et al. | Oct 2005 | A1 |
20050261562 | Zhou | Nov 2005 | A1 |
20050261660 | Choi | Nov 2005 | A1 |
20050277912 | John | Dec 2005 | A1 |
20060009727 | O'Mahony et al. | Jan 2006 | A1 |
20060079809 | Goldberger et al. | Apr 2006 | A1 |
20060100494 | Kroll | May 2006 | A1 |
20060134323 | O'Brien | Jun 2006 | A1 |
20060167350 | Monfre et al. | Jul 2006 | A1 |
20060173406 | Hayes et al. | Aug 2006 | A1 |
20060189925 | Gable et al. | Aug 2006 | A1 |
20060189926 | Hall et al. | Aug 2006 | A1 |
20060197015 | Sterling et al. | Sep 2006 | A1 |
20060200070 | Callicoat et al. | Sep 2006 | A1 |
20060204535 | Johnson | Sep 2006 | A1 |
20060229531 | Goldberger et al. | Oct 2006 | A1 |
20060253085 | Geismar et al. | Nov 2006 | A1 |
20060264895 | Flanders | Nov 2006 | A1 |
20060270983 | Lord | Nov 2006 | A1 |
20060276771 | Galley et al. | Dec 2006 | A1 |
20060282290 | Flaherty et al. | Dec 2006 | A1 |
20070016127 | Staib et al. | Jan 2007 | A1 |
20070060796 | Kim | Mar 2007 | A1 |
20070060869 | Tolle et al. | Mar 2007 | A1 |
20070060872 | Hall et al. | Mar 2007 | A1 |
20070083160 | Hall et al. | Apr 2007 | A1 |
20070106135 | Sloan et al. | May 2007 | A1 |
20070116601 | Patton | May 2007 | A1 |
20070118405 | Campbell et al. | May 2007 | A1 |
20070129690 | Rosenblatt et al. | Jun 2007 | A1 |
20070142720 | Ridder et al. | Jun 2007 | A1 |
20070173761 | Kanderian et al. | Jul 2007 | A1 |
20070173974 | Lin | Jul 2007 | A1 |
20070179352 | Randlov et al. | Aug 2007 | A1 |
20070191716 | Goldberger et al. | Aug 2007 | A1 |
20070197163 | Robertson | Aug 2007 | A1 |
20070225675 | Robinson et al. | Sep 2007 | A1 |
20070244381 | Robinson et al. | Oct 2007 | A1 |
20070249007 | Rosero | Oct 2007 | A1 |
20070264707 | Liederman et al. | Nov 2007 | A1 |
20070282269 | Carter et al. | Dec 2007 | A1 |
20070287985 | Estes et al. | Dec 2007 | A1 |
20070293843 | Ireland et al. | Dec 2007 | A1 |
20080051764 | Dent et al. | Feb 2008 | A1 |
20080058625 | McGarraugh et al. | Mar 2008 | A1 |
20080065050 | Sparks et al. | Mar 2008 | A1 |
20080071157 | McGarraugh et al. | Mar 2008 | A1 |
20080071158 | McGarraugh et al. | Mar 2008 | A1 |
20080078400 | Martens et al. | Apr 2008 | A1 |
20080097289 | Steil et al. | Apr 2008 | A1 |
20080132880 | Buchman | Jun 2008 | A1 |
20080161664 | Mastrototaro et al. | Jul 2008 | A1 |
20080172026 | Blomquist | Jul 2008 | A1 |
20080177165 | Blomquist et al. | Jul 2008 | A1 |
20080188796 | Steil et al. | Aug 2008 | A1 |
20080200838 | Goldberger et al. | Aug 2008 | A1 |
20080206067 | De Corral | Aug 2008 | A1 |
20080208113 | Damiano et al. | Aug 2008 | A1 |
20080214919 | Harmon et al. | Sep 2008 | A1 |
20080228056 | Blomquist et al. | Sep 2008 | A1 |
20080249386 | Besterman et al. | Oct 2008 | A1 |
20080269585 | Ginsberg | Oct 2008 | A1 |
20080269723 | Mastrototaro et al. | Oct 2008 | A1 |
20080287906 | Burkholz et al. | Nov 2008 | A1 |
20090006061 | Thukral et al. | Jan 2009 | A1 |
20090018406 | Yodfat et al. | Jan 2009 | A1 |
20090030398 | Yodfat et al. | Jan 2009 | A1 |
20090036753 | King | Feb 2009 | A1 |
20090043240 | Robinson et al. | Feb 2009 | A1 |
20090054753 | Robinson et al. | Feb 2009 | A1 |
20090069743 | Krishnamoorthy et al. | Mar 2009 | A1 |
20090069787 | Estes et al. | Mar 2009 | A1 |
20090099521 | Gravesen et al. | Apr 2009 | A1 |
20090131861 | Braig et al. | May 2009 | A1 |
20090156922 | Goldberger et al. | Jun 2009 | A1 |
20090221890 | Saffer et al. | Sep 2009 | A1 |
20090228214 | Say et al. | Sep 2009 | A1 |
20090318791 | Kaastrup | Dec 2009 | A1 |
20090326343 | Gable et al. | Dec 2009 | A1 |
20100057042 | Hayter | Mar 2010 | A1 |
20100114026 | Karratt et al. | May 2010 | A1 |
20100121170 | Rule | May 2010 | A1 |
20100137784 | Cefai et al. | Jun 2010 | A1 |
20100152658 | Hanson et al. | Jun 2010 | A1 |
20100211003 | Sundar | Aug 2010 | A1 |
20100295686 | Sloan et al. | Nov 2010 | A1 |
20110054390 | Searle et al. | Mar 2011 | A1 |
20110054399 | Chong et al. | Mar 2011 | A1 |
20110124996 | Reinke et al. | May 2011 | A1 |
20110144586 | Michaud et al. | Jun 2011 | A1 |
20110160652 | Yodat et al. | Jun 2011 | A1 |
20110178472 | Cabiri | Jul 2011 | A1 |
20110190694 | Lanier, Jr. | Aug 2011 | A1 |
20110202005 | Yodfat | Aug 2011 | A1 |
20110218495 | Remde | Sep 2011 | A1 |
20110230833 | Landman et al. | Sep 2011 | A1 |
20110251509 | Beyhan et al. | Oct 2011 | A1 |
20110316562 | Cefai et al. | Dec 2011 | A1 |
20120003935 | Lydon et al. | Jan 2012 | A1 |
20120010594 | Holt et al. | Jan 2012 | A1 |
20120030393 | Ganesh et al. | Feb 2012 | A1 |
20120053556 | Lee | Mar 2012 | A1 |
20120078067 | Kovatchev et al. | Mar 2012 | A1 |
20120078161 | Masterson et al. | Mar 2012 | A1 |
20120078181 | Smith | Mar 2012 | A1 |
20120101451 | Boit | Apr 2012 | A1 |
20120190955 | Rao et al. | Jul 2012 | A1 |
20120203178 | Tverskoy | Aug 2012 | A1 |
20120226259 | Yodfat et al. | Sep 2012 | A1 |
20120238851 | Kamen et al. | Sep 2012 | A1 |
20120271655 | Knobel et al. | Oct 2012 | A1 |
20120277668 | Chawla | Nov 2012 | A1 |
20120282111 | Nip | Nov 2012 | A1 |
20120295550 | Wilson et al. | Nov 2012 | A1 |
20130030358 | Yodfat et al. | Jan 2013 | A1 |
20130178791 | Javitt | Jul 2013 | A1 |
20130253472 | Cabiri | Sep 2013 | A1 |
20130296823 | Melker et al. | Nov 2013 | A1 |
20130317753 | Kamen | Nov 2013 | A1 |
20130338576 | O'Connor | Dec 2013 | A1 |
20140005633 | Finan | Jan 2014 | A1 |
20140066886 | Roy et al. | Mar 2014 | A1 |
20140074033 | Sonderegger et al. | Mar 2014 | A1 |
20140128839 | Dilanni et al. | May 2014 | A1 |
20140135880 | Baumgartner et al. | May 2014 | A1 |
20140146202 | Boss et al. | May 2014 | A1 |
20140200426 | Taub et al. | Jul 2014 | A1 |
20140230021 | Birtwhistle et al. | Aug 2014 | A1 |
20140276554 | Finan et al. | Sep 2014 | A1 |
20140276556 | Saint | Sep 2014 | A1 |
20140309615 | Mazlish | Oct 2014 | A1 |
20140316379 | Sonderegger et al. | Oct 2014 | A1 |
20140325065 | Birtwhistle et al. | Oct 2014 | A1 |
20150120317 | Mayou et al. | Apr 2015 | A1 |
20150134265 | Kohlbrecher et al. | May 2015 | A1 |
20150165119 | Palerm et al. | Jun 2015 | A1 |
20150173674 | Hayes et al. | Jun 2015 | A1 |
20150217052 | Keenan et al. | Aug 2015 | A1 |
20150217053 | Booth et al. | Aug 2015 | A1 |
20150265767 | Vazquez et al. | Sep 2015 | A1 |
20150351671 | Vanslyke et al. | Dec 2015 | A1 |
20150366945 | Greene | Dec 2015 | A1 |
20160015891 | Papiorek | Jan 2016 | A1 |
20160038673 | Morales | Feb 2016 | A1 |
20160038689 | Lee et al. | Feb 2016 | A1 |
20160051749 | Istoc | Feb 2016 | A1 |
20160089494 | Guerrini | Mar 2016 | A1 |
20160175520 | Palerm et al. | Jun 2016 | A1 |
20160228641 | Gescheit et al. | Aug 2016 | A1 |
20160243318 | Despa et al. | Aug 2016 | A1 |
20160256087 | Doyle, III | Sep 2016 | A1 |
20160302054 | Kimura et al. | Oct 2016 | A1 |
20160331310 | Kovatchev | Nov 2016 | A1 |
20160354543 | Cinar et al. | Dec 2016 | A1 |
20170049386 | Abraham et al. | Feb 2017 | A1 |
20170143900 | Rioux et al. | May 2017 | A1 |
20170173261 | O'Connor | Jun 2017 | A1 |
20170189625 | Cirillo | Jul 2017 | A1 |
20170281877 | Marlin et al. | Oct 2017 | A1 |
20170296746 | Chen et al. | Oct 2017 | A1 |
20170311903 | Davis et al. | Nov 2017 | A1 |
20170348482 | Duke et al. | Dec 2017 | A1 |
20180036495 | Searle | Feb 2018 | A1 |
20180040255 | Freeman et al. | Feb 2018 | A1 |
20180075200 | Davis et al. | Mar 2018 | A1 |
20180075201 | Davis et al. | Mar 2018 | A1 |
20180075202 | Davis et al. | Mar 2018 | A1 |
20180092576 | Ambrosio | Apr 2018 | A1 |
20180126073 | Wu et al. | May 2018 | A1 |
20180169334 | Grosman et al. | Jun 2018 | A1 |
20180200434 | Mazlish et al. | Jul 2018 | A1 |
20180200438 | Mazlish et al. | Jul 2018 | A1 |
20180200441 | Desborough et al. | Jul 2018 | A1 |
20180204636 | Edwards | Jul 2018 | A1 |
20180289891 | Finan et al. | Oct 2018 | A1 |
20180296757 | Finan et al. | Oct 2018 | A1 |
20180342317 | Skirble et al. | Nov 2018 | A1 |
20180369479 | Hayter et al. | Dec 2018 | A1 |
20190076600 | Grosman et al. | Mar 2019 | A1 |
20190240403 | Palerm et al. | Aug 2019 | A1 |
20190290844 | Monirabbasi et al. | Sep 2019 | A1 |
20190336683 | O'Connor et al. | Nov 2019 | A1 |
20190336684 | O'Connor et al. | Nov 2019 | A1 |
20190348157 | Booth et al. | Nov 2019 | A1 |
20200046268 | Patek et al. | Feb 2020 | A1 |
20200101222 | Lintereur et al. | Apr 2020 | A1 |
20200101223 | Lintereur | Apr 2020 | A1 |
20200101225 | O'Connor et al. | Apr 2020 | A1 |
20200219625 | Kahlbaugh | Jul 2020 | A1 |
20200342974 | Chen et al. | Oct 2020 | A1 |
20210050085 | Hayter et al. | Feb 2021 | A1 |
20210098105 | Lee et al. | Apr 2021 | A1 |
20220023536 | Graham et al. | Jan 2022 | A1 |
Number | Date | Country |
---|---|---|
2015200834 | Mar 2015 | AU |
1297140 | May 2001 | CN |
19756872 | Jul 1999 | DE |
0341049 | Nov 1989 | EP |
0496305 | Jul 1992 | EP |
0549341 | Jun 1993 | EP |
1491144 | Dec 2004 | EP |
1571582 | Sep 2005 | EP |
0801578 | Jul 2006 | EP |
2666520 | Oct 2009 | EP |
2139382 | Jan 2010 | EP |
2397181 | Dec 2011 | EP |
2695573 | Feb 2014 | EP |
2830499 | Feb 2015 | EP |
2897071 | May 2019 | EP |
3607985 | Feb 2020 | EP |
2443261 | Apr 2008 | GB |
51125993 | Nov 1976 | JP |
02131777 | May 1990 | JP |
2004283378 | Oct 2004 | JP |
2017525451 | Sep 2017 | JP |
2018153569 | Oct 2018 | JP |
2019525276 | Sep 2019 | JP |
200740148 | Oct 2007 | TW |
M452390 | May 2013 | TW |
9800193 | Jan 1998 | WO |
9956803 | Nov 1999 | WO |
0030705 | Jun 2000 | WO |
0032258 | Jun 2000 | WO |
0172354 | Oct 2001 | WO |
2002015954 | Feb 2002 | WO |
0243866 | Jun 2002 | WO |
02082990 | Oct 2002 | WO |
03016882 | Feb 2003 | WO |
03039362 | May 2003 | WO |
03045233 | Jun 2003 | WO |
2004043250 | May 2004 | WO |
04092715 | Oct 2004 | WO |
2005051170 | Jun 2005 | WO |
2005082436 | Sep 2005 | WO |
05110601 | Nov 2005 | WO |
2006053007 | May 2006 | WO |
2007064835 | Jun 2007 | WO |
2007078937 | Jul 2007 | WO |
2008024810 | Feb 2008 | WO |
2008029403 | Mar 2008 | WO |
2008133702 | Nov 2008 | WO |
2009045462 | Apr 2009 | WO |
2009049252 | Apr 2009 | WO |
2009066287 | May 2009 | WO |
2009066288 | May 2009 | WO |
2009098648 | Aug 2009 | WO |
2009134380 | Nov 2009 | WO |
2010053702 | May 2010 | WO |
2010132077 | Nov 2010 | WO |
2010138848 | Dec 2010 | WO |
2010147659 | Dec 2010 | WO |
2011095483 | Aug 2011 | WO |
2012045667 | Apr 2012 | WO |
2012108959 | Aug 2012 | WO |
2012134588 | Oct 2012 | WO |
2013078200 | May 2013 | WO |
2013134486 | Sep 2013 | WO |
20130149186 | Oct 2013 | WO |
2013177565 | Nov 2013 | WO |
2013182321 | Dec 2013 | WO |
2014194183 | Dec 2014 | WO |
2015056259 | Apr 2015 | WO |
2015081337 | Jun 2015 | WO |
2015187366 | Dec 2015 | WO |
2016004088 | Jan 2016 | WO |
2016041873 | Mar 2016 | WO |
2016089702 | Jun 2016 | WO |
2016141082 | Sep 2016 | WO |
2016161254 | Oct 2016 | WO |
2017091624 | Jun 2017 | WO |
2017105600 | Jun 2017 | WO |
2017184988 | Oct 2017 | WO |
2017205816 | Nov 2017 | WO |
2018009614 | Jan 2018 | WO |
2018067748 | Apr 2018 | WO |
2018120104 | Jul 2018 | WO |
2018136799 | Jul 2018 | WO |
2018204568 | Nov 2018 | WO |
2019077482 | Apr 2019 | WO |
2019094440 | May 2019 | WO |
2019213493 | Nov 2019 | WO |
2019246381 | Dec 2019 | WO |
2020081393 | Apr 2020 | WO |
2021011738 | Jan 2021 | WO |
Entry |
---|
US 5,954,699 A, 09/1999, Jost et al. (withdrawn) |
International Search Report and Written Opinion for the International Patent Application No. PCT/US2020/052125, dated Aug. 12, 2020, 15 pages. |
International Search Report and Written Opinion for the International Patent Application No. PCT/US2020/050332, dated Sep. 12, 2020, 12 pages. |
European Patent Office, “Notification of Transmittal of the ISR and the Written Opinion of the International Searching Authority, or the Declaration,” in PCT Application No. PCT/GB2015/050248, dated Jun. 23, 2015, 12 pages. |
International Search Report and Written Opinion for International Patent Application No. PCT/US2021/051027, dated Jan. 7, 2022, 16 pages. |
International Search Report and Written Opinion for International Patent Application No. PCT/US2021/052372, dated Jan. 26, 2022, 15 pages. |
International Search Report and Written Opinion for the International Patent Application No. PCT/US2021/046607, dated Jan. 31, 2022, 20 pages. |
International Search Report and Written Opinion for the International Patent Application No. PCT/US2021/055745, dated Feb. 14, 2022, 13 pages. |
European Search Report for the European Patent Application No. 21168591.2, dated Oct. 13, 2021, 4 pages. |
International Search Report and Written Opinion for the International Patent Application No. PCT/US2021/041954, dated Oct. 25, 2021, 13 pages. |
International Search Report and Written Opinion for the International Patent Application No. PCT/US2021/047771, dated Dec. 22, 2021, 11 pages. |
International Search Report and Written Opinion for the International Patent Application No. PCT/US2021/052855, dated Dec. 22, 2021, 11 pages. |
Unger, Jeff, et al., “Glucose Control in the Hospitalized Patient,” Emerg. Med 36(9):12-18 (2004). |
Glucommander FAQ downloaded from https://adaendo.com/GlucommanderFAQ.html on Mar. 16, 2009. |
Finfer, Simon & Heritier, Stephane. (2009). The NICE-SUGAR (Normoglycaemia in Intensive Care Evaluation and Survival Using Glucose Algorithm Regulation) Study: statistical analysis plan. Critical care and resuscitation : journal of the Australasian Academy of Critical Care Medicine. 11. 46-57. |
Letters to the Editor regarding “Glucose Control in Critically III Patients,” N Engl J Med 361: 1, Jul. 2, 2009. |
“Medtronic is Leading a Highly Attractive Growth Market,” Jun. 2, 2009. |
Davidson, Paul C., et al. “Glucommander: An Adaptive, Computer-Directed System for IV Insulin Shown to be Safe, Simple, and Effective in 120,618 Hours of Operation,” Atlanta Diabetes Associates presentation Nov. 16, 2003. |
Davidson, Paul C., et al. “Pumpmaster and Glucommander,” presented at the MiniMed Symposium, Atlanta GA, Dec. 13, 2003. |
Kanji S., et al. “Reliability of point-of-care testing for glucose measurement in critically ill adults,” Critical Care Med, vol. 33, No. 12, pp. 2778-2785, 2005. |
Krinsley James S., “Severe hypoglycemia in critically ill patients: Risk factors and outcomes,” Critical Care Med, vol. 35, No. 10, pp. 1-6, 2007. |
International Searching Authority, Invitation to Pay Additional Fees, International Application No. PCT/US2006/004929, dated Jul. 27, 2006. |
Farkas et al. ““Single-Versus Triple-Lumen Central Catheter-Related Sepsis: A Prospective Randomized Study in a Critically III Population”” The American Journal of Medicine Sep. 1992vol. 93 p. 277-282. |
Davidson, Paul C., et al., A computer-directed intravenous insulin system shown to be safe, simple,and effective in 120,618 h of operation. Diabetes Care, vol. 28, No. 10, Oct. 2005, pp. 2418-2423. |
International Search Report and Written Opinion for the International Patent Application No. PCT/US2021/016283, dated Jun. 2, 2021, 15 pages. |
Gorke, A. “Microbial contamination of haemodialysis catheter connections.” EDTNA/ERCA journal (English ed.) vol. 31,2 (2005): 79-84. doi:10.1111/j.1755-6686.2005.tb00399.x. |
Lovich et al. “Central venous catheter infusions: A laboratory model shows large differences in drug delivery dynamics related to catheter dead volume” Critical Care Med 2007 vol. 35, No. 12. |
Van Den Berghe, Greet, M.D., Ph.D., et al., Intensive Insulin Therapy in Critically III Patients, The New England Journal of Medicine, vol. 345, No. 19, Nov. 8, 2001, pp. 1359-1367. |
Templeton et al., “Multilumen Central Venous Catheters Increase Risk for Catheter-Related Bloodstream Infection: Prospective Surveillance Study” Infection 2008; 36: 322-327. |
Wilson, George S., et al., Progress toward the Development of an Implantable Sensor for Glucose, Clin. Chem., vol. 38, No. 9, 1992, pp. 1613-1617. |
Yeung et al. “Infection Rate for Single Lumen v Triple Lumen Subclavian Catheters” Infection Control and Hospital Epidemiology, vol. 9, No. 4 (Apr. 1988) pp. 154-158 The University of Chicago Press. |
International Search Report and Written Opinion, International Application No. PCT/US2010/033794 dated Jul. 16, 2010. |
International Search Report and Written Opinion in PCT/US2008/079641 dated Feb. 25, 2009. |
Berger, ““Measurement of Analytes in Human Serum and Whole Blood Samples by Near-Infrared Raman Spectroscopy,”” Ph.D. Thesis, Massachusetts Institute of Technology, Chapter 4, pp. 50-73, 1998. |
Berger, “An Enhanced Algorithm for Linear Multivariate Calibration,” Analytical Chemistry, vol. 70, No. 3, pp. 623-627, Feb. 1, 1998. |
Billman et al., “Clinical Performance of an In line Ex-Vivo Point of Care Monitor: A Multicenter Study,” Clinical Chemistry 48: 11, pp. 2030-2043, 2002. |
Widness et al., “Clinical Performance on an In-Line Point-of-Care Monitor in Neonates”; Pediatrics, vol. 106, No. 3, pp. 497-504, Sep. 2000. |
Finkielman et al., “Agreement Between Bedside Blood and Plasma Glucose Measurement in the ICU Setting” retrieved from http://www.chestjournal.org; CHEST/127/5/May 2005. |
Glucon Critical Care Blood Glucose Monitor; Glucon; retrieved from http://www.glucon.com. |
Fogt, et al., “Development and Evaluation of a Glucose Analyzer for a Glucose-Controlled Insulin Infusion System (Biostator)”; Clinical Chemistry, vol. 24, No. 8, pp. 1366-1372, 1978. |
Vonach et al., “Application of Mid-Infrared Transmission Spectrometry to the Direct Determination of Glucose in Whole Blood,” Applied Spectroscopy, vol. 52, No. 6, 1998, pp. 820-822. |
Muniyappa et al., “Current Approaches for assessing insulin sensitivity and resistance in vivo: advantages, limitations, and appropriate usage,” AJP-Endocrinol Metab, vol. 294, E15-E26, first published Oct. 23, 2007. |
R Anthony Shaw, et al., “Infrared Spectroscopy in Clinical and Dianostic Analysis,” Encyclopedia of Analytical Chemistry, ed. Robert A. Meyers, John Wiley & Sons, Ltd., pp. 1-20, 2000. |
International Preliminary Report on Patentability for the International Patent Application No. PCT/US2019/053603, dated Apr. 8, 2021, 9 pages. |
International Search Report and Written Opinion for the International Patent Application No. PCT/US2019/053603, dated Jan. 7, 2020, 16 pages. |
Dassau et al., “Detection of a meal using continuous glucose monitoring: Implications for an artificial [beta]-cell.” Diabetes Care, American Diabetes Association, Alexandria, VA, US, 31(2):295-300 (2008). |
Cameron et al., “Probabilistic Evolving Meal Detection and Estimation of Meal Total Glucose Appearance Author Affiliations”, J Diabetes Sci and Tech.Vol., Diabetes Technology Society ;(5):1022-1030 (2009). |
Lee et al., “A closed-loop artificial pancreas based on model predictive control: Human-friendly identification and automatic meal disturbance rejection”, Biomedical Signal Processing and Control, Elsevier, Amsterdam, NL, 4 (4):1746-8094 (2009). |
International Search Report and Written Opinion for the IntemationalPatent Application No. PCT/US2021/018297, dated May 18, 2021, 18 pages. |
An Emilia Fushimi: “Artificial Pancreas: Evaluating the ARG Algorithm Without Meal Announcement”, Journal of Diabetes Science and Technology Diabetes Technology Society, Mar. 22, 2019, pp. 1025-1043. |
International Search Report and Written Opinion for the International Patent Application No. PCT/US2021/017441, dated May 25, 2021, 12 pages. |
International Search Report and Written Opinion for the IntemationalPatent Application No. PCT/US2021/017664, dated May 26, 2021, 16 pages. |
Mirko Messori et al: “Individualized model predictive control for the artificial pancreas: In silico evaluation of closed-loop glucose control”, IEEE Control Systems, vol. 38, No. 1, Feb. 1, 2018, pp. 86-104. |
International Search Report and Written Opinion for the International Patent Application No. PCT/US2021/017662, dated May 26, 2021, 14 pages. |
Anonymous: “Reservoir Best Practice and Top Tips” Feb. 7, 2016, URL: https://www.medtronic-diabetes.co.uk/blog/reservoir-best-practice-and-top-tips, p. 1. |
Gildon Bradford: “InPen Smart Insulin Pen System: Product Review and User Experience” Diabetes Spectrum, vol. 31, No. 4, Nov. 15, 2018, pp. 354-358. |
International Search Report and Written Opinion for the International Patent Application No. PCT/US2021/016050, dated May 27, 2021, 16 pages. |
International Search Report and Written Opinion for the International Patent Application No. PCT/US2020/065226, dated May 31, 2021, 18 pages. |
International Search Report and Written Opinion for the International Patent Application No. PCT/US2021/017659, dated May 31, 2021, 13 pages. |
Montaser Eslam et al., “Seasonal Local Models for Glucose Prediction in Type 1 Diabetes”, IEE Journal of Biomedical and Health Informatics, IEEE, Piscataway, NJ, USA, vol. 24, No. 7, Jul. 2020, pp. 2064-2072. |
Samadi Sediqeh et al., “Automatic Detection and Estimation of Unannouced Meals for Multivariable Artificial Pancreas System”, Diabetis Technology & Therapeutics, vol. 20m No. 3, Mar. 1, 2018, pp. 235-246. |
Samadi Sediqeh et al., “Meal Detection and Carbohydrate Estimation Using Continuous Glucose Sensor Data” IEEE Journal of Biomedical and Health Informatics, IEEE, Piscataway, NJ, USA, vol. 21, No. 3, May 1, 2017, pp. 619-627. |
Khodaei et al., “Physiological Closed-Loop Contol (PCLC) Systems: Review of a Modern Frontier in Automation”, IEEE Access, IEEE, USA, vol. 8, Jan. 20, 2020, pp. 23965-24005. |
E. Atlas et al., “MD-Logic Artificial Pancreas System: A pilot study in adults with type 1 diabetes”, Diabetes Care, vol. 33, No. 5, Feb. 11, 2010, pp. 1071-1076. |
Anonymous: “Fuzzy control system”, Wikipedia, Jan. 10, 2020. URL: https://en.wikipedia.org/wlindex.php?title=Fuzzy_control_system&oldid=935091190 Retrieved: May 25, 2021. |
International Search Report and Written Opinion for the International Patent Application No. PCT/US2021/022694, dated Jun. 25, 2021, 13 pages. |
International Search Report and Written Opinion for the Application No. PCT/US2017/015601, dated May 16, 2017, 12 pages. |
International Search Report and Written Opinion for the Application No. PCT/US2018/018901, dated Aug. 6, 2018, 12 pages. |
International Search Report and Written Opinion for Application No. PCT/US2018/052467, dated Jan. 4, 2019, 13 pages. |
“How to Create a QR Code that Deep Links to Your Mobile App”, Pure Oxygen Labs, web<https://pureoxygenlabs.com/how-to-create-a-qr-codes-that-deep-link-to-your-mobile-app/>. Year:2017. |
“Read NFC Tags with an iPHone App on iOS 11”, GoToTags, Sep. 11, 2017, web <https://gototags.com/blog/read-nfc-tags-with-an-iphone-app-on-ios-11/>. (Year:2017). |
International Search Report and Written Opinion for International Application No. PCT/US2016/063350, dated Mar. 27, 2017, 9 pages. |
PCT International Search Report and Written Opinion dated Apr. 29, 2015, received in corresponding PCT Application No. PCT/US16/18452, 9 pages. |
International Preliminary Report on Patentability dated Aug. 31, 2017, issued in PCT Patent Application No. PCT/US2016/018452, 7 pages. |
International Search Report and Written Opinion for the International Patent Application No. PCT/US2022/013470, dated May 6, 2022, 14 pages. |
International Search Report and Written Opinion for the International Patent Application No. PCT/US2022/013473, dated May 6, 2022, 13 pages. |
International Search Report and Written Opinion for the International Patent Application No. PCT/US2022/019079, dated Jun. 2, 2022, 14 pages. |
International Search Report and Written Opinion for the International Patent Application No. PCT/US2022/018453, dated Jun. 2, 2022, 13 pages. |
International Search Report and Written Opinion for the International Patent Application No. PCT/US22/018700, dated Jun. 7, 2022, 13 pages. |
International Search Report and Written Opinion for the International Patent Application No. PCT/US22/019080, dated Jun. 7, 2022, 14 pages. |
International Search Report and Written Opinion for the International Patent Application No. PCT/US22/019664, dated Jun. 7, 2022, 14 pages. |
Herrero Pau et al: “Enhancing automatic closed-loop glucose control in type 1 diabetes with an adaptive meal bolus calculator-in silicoevaluation under intra-day variability”, Computer Methods and Programs in Biomedicine, Elsevier, Amsterdam, NL, vol. 146, Jun. 1, 2017 (Jun. 1, 2017), pp. 125-131, XP085115607, ISSN: 0169-2607, DOI:10.1016/J.CMPB.2017.05.010. |
Herrero Pau Ei Al: “Enhancing automatic closed-loop glucose control in type 1 diabetes with an adaptive meal polus calculator-in silicoevaluation under intra-day variability”, Computer Methods and Programs in Biomedicine, Elsevier, Amsterdam, Nl, vol. 146, Jun. 1, 2017 (2017-06-01), pp. 125-131, XP085115607, Ssn: 0169-2607, D0l:10.1016/J.CMPB.2017.05.010. |
Marie Aude Qemerais: “Preliminary Evaluation of a New Semi-Closed-Loop Insulin Therapy System over the prandial period in Adult Patients with type I diabetes: the WP6. 0 Diabeloop Study”, Journal of Diabetes Science and Technology Diabetes Technology Society Reprints and permissions, Jan. 1, 2014, p. 1177-1184, Retrieved from the Internet: URL:http://journals.sagepub.com/doi/pdf/10.1177/1932296814545668 [retrieved on Jun. 6, 2022] chapter “Functioning of the Algorithm” chapter “Statistical Analysis” p. 1183, left-hand col. line 16- line 23. |
Anonymous: “Kernel density estimation”, Wikipedia, Nov. 13, 2020 (Nov. 13, 2020), pp. 1-12, XP055895569, Retrieved from the Internet: URL:https://en.wikipedia.org/w/index.php?title=Kemnel_density_estimation&oldid=988508333 [retrieved on Jun. 6, 2022]. |
Anonymous: “openaps / oref0 /lib/determine-basal-js”, openaps repository, Nov. 9, 2019 (Nov. 9, 2019), pp. 1-17, XP055900283, Retrieved from the Internet: URL:https://github.com/openaps/oref0/blob/master/lib/determine-basal/determine-basal.js [retrieved on Jun. 6, 2022] line 116-line 118, line 439-line 446. |
Anonymous: “AndroidAPS screens”, AndroidAPS documentation, Oct. 4, 2020 (Oct. 4, 2020), pp. 1-12, XP055894824, Retrieved from the Internet: URL:https://github.com/openaps/AndroidAPSdocs/blob/25d8acf8b28262b411b34f416f173ac0814d7e14/docs/EN/Getting-Started/Screenshots.md [retrieved on Jun. 6, 2022]. |
Kozak Milos et al: “Issue #2473 of AndroidAPS”, MilosKozak / AndroidAPS Public repository, Mar. 4, 2020 (Mar. 4, 2020), pp. 1-4, XP055900328, Retrieved from the Internet: URL:https://github.com/MilosKozak/AndroidAPS/issues/2473 [retrieved on Jun. 6, 2022]. |
Medication Bar Code System Implementation Planning Section I: A Bar Code Primer for Leaders, Aug. 2013. |
Medication Bar Code System Implementation Planning Section II: Building the Case for Automated Identification of Medications, Aug. 2013. |
Villareal et al. (2009) in: Distr. Comp. Art. Intell. Bioninf. Soft Comp. Amb. Ass. Living; Int. Work Conf. Art. Neural Networks (IWANN) 2009, Lect. Notes Comp. Sci. vol. 5518; S. Omatu et al. (Eds.), pp. 870-877. |
Fox, Ian G.; Machine Learning for Physiological Time Series: Representing and Controlling Blood Glucose for Diabetes Management; University of Michigan. ProQuest Dissertations Publishing, 2020. 28240142. (Year: 2020). |
International Search Report and Written Opinion for the International Patent Application No. PCT/US2022/012896, dated Apr. 22, 2022, 15 pages. |
Number | Date | Country | |
---|---|---|---|
20200338264 A1 | Oct 2020 | US |
Number | Date | Country | |
---|---|---|---|
62398792 | Sep 2016 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 15714496 | Sep 2017 | US |
Child | 16884802 | US |